GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » COGS-to-Revenue

Shire (SHPG) COGS-to-Revenue : 0.30 (As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire COGS-to-Revenue?

Shire's Cost of Goods Sold for the three months ended in Sep. 2018 was $1,158 Mil. Its Revenue for the three months ended in Sep. 2018 was $3,872 Mil.

Shire's COGS to Revenue for the three months ended in Sep. 2018 was 0.30.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Shire's Gross Margin % for the three months ended in Sep. 2018 was 70.10%.


Shire COGS-to-Revenue Historical Data

The historical data trend for Shire's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire COGS-to-Revenue Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.16 0.15 0.33 0.31

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.30 0.30 0.28 0.30

Shire COGS-to-Revenue Calculation

Shire's COGS to Revenue for the fiscal year that ended in Dec. 2017 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4700.8 / 15160.6
=0.31

Shire's COGS to Revenue for the quarter that ended in Sep. 2018 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1157.6 / 3871.7
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire  (NAS:SHPG) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Shire's Gross Margin % for the three months ended in Sep. 2018 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1157.6 / 3871.7
=70.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Shire COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shire's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085

Shire (SHPG) Headlines

From GuruFocus

Shire Completes Sale of Oncology Franchise

By Marketwired Marketwired 08-31-2018

David Abrams Buys Shire, Boosts Lithia Motors

By Tiziano Frateschi Tiziano Frateschi 11-14-2018